Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen

Key Points

• Pyxis Oncology received an upgrade from a "sell" to a "hold" rating by Wall Street Zen, indicating increased confidence in the stock's performance.
• The stock currently has a consensus target price of $8.67, with three analysts rating it a "Buy" and two a "Hold".
• Pyxis Oncology reported an earnings per share of ($0.30) for the last quarter, surpassing analysts' expectations and showing potential for growth.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Sunday.

Other equities analysts also recently issued research reports about the company. Zacks Research raised Pyxis Oncology from a "strong sell" rating to a "hold" rating in a research report on Monday, August 18th. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price target on shares of Pyxis Oncology in a research report on Tuesday, August 19th. Three analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Pyxis Oncology has a consensus rating of "Moderate Buy" and a consensus target price of $8.67.

Pyxis Oncology Stock Up 1.5%

NASDAQ:PYXS opened at $1.34 on Friday. Pyxis Oncology has a twelve month low of $0.8332 and a twelve month high of $5.3899. The business has a 50 day moving average price of $1.16 and a two-hundred day moving average price of $1.15. The company has a market cap of $83.11 million, a P/E ratio of -0.84 and a beta of 1.13.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.06. The firm had revenue of $2.82 million for the quarter. As a group, analysts anticipate that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pyxis Oncology

Several large investors have recently made changes to their positions in the stock. Bridgeway Capital Management LLC boosted its holdings in shares of Pyxis Oncology by 76.1% in the 2nd quarter. Bridgeway Capital Management LLC now owns 142,295 shares of the company's stock valued at $157,000 after buying an additional 61,500 shares during the last quarter. Jane Street Group LLC bought a new stake in Pyxis Oncology in the 2nd quarter valued at $370,000. Velan Capital Investment Management LP bought a new stake in Pyxis Oncology in the 2nd quarter valued at $44,000. Qube Research & Technologies Ltd raised its stake in Pyxis Oncology by 128.4% in the 2nd quarter. Qube Research & Technologies Ltd now owns 103,063 shares of the company's stock valued at $113,000 after acquiring an additional 57,935 shares during the period. Finally, Marshall Wace LLP bought a new stake in Pyxis Oncology in the 2nd quarter valued at $163,000. Institutional investors and hedge funds own 39.09% of the company's stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.